SC
MLTX icon

Shay Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Shay Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,500
Closed -$485K – 441
2023
Q2 		$485K Buy
+9,500
New +$256K 0.07% 176

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Shay Capital's MLTX Position: Q3 2023 in Review

Shay Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2023, closing a stake of 9,500 shares — an estimated $485K sold.

Shay Capital first reported a position in MLTX in Q2 2023 and held it in 1 quarter. The position peaked at $485K in Q2 2023. 118 funds tracked by Wall St. Rank hold MLTX as of Q3 2023.

  • Shay Capital reported no remaining MoonLake Immunotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Shay Capital sold 9,500 MoonLake Immunotherapeutics shares in Q3 2023, an estimated $485K.
  • Shay Capital first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 1 quarter.
  • Shay Capital's MoonLake Immunotherapeutics position peaked at $485K in Q2 2023.
  • 118 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2023.

Based on Shay Capital's 13F filing for Q3 2023, filed 14 Nov 2023.